Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New Method Proposed to Show Equivalence of Generics and Original Drugs
March 1, 2010
- CDFS Recommends Approval for Vectibix from Takeda
March 1, 2010
- Eliminate Distinction between Clinical Research and Trials, Introduce IND System: Prof. Kawakami
March 1, 2010
- Shionogi Applies for Rapiacta for Pediatric Use
March 1, 2010
- Consider Ethnic Diversity at Early Stage of Drug Development: Dr Iwasaki
March 1, 2010
- Olmetec Approved for Children, Adolescents Aged 6-16
March 1, 2010
- Takeda Begins PIII Program for Hematide in Japan
March 1, 2010
- 1st Meeting Held by Panel on Unapproved Drugs with Unmet Medical Need
February 22, 2010
- Healthcare Is Opportunity for Investment: Mr Wachi
February 22, 2010
- Doctors Assess MRs Based on Their Expertise
February 22, 2010
- DPJ Lawmaker Calls For Promotion of Pharma Industry
February 22, 2010
- FUJIFILM Embarks on Generics Business Aiming at ¥50.0 Bil. Sales in FY2014
February 22, 2010
- Novartis' Sales Up 8.2% in 2009 Driven by Diovan, Glivec
February 22, 2010
- Cost Necessary to Revitalize Healthcare Estimated by a Team: Dr Adachi
February 22, 2010
- GSK's Sales Up 22% in Japan
February 22, 2010
- 9 New Drugs to Be Reviewed on February 26
February 22, 2010
- JMHA to Offer DB to Its Members to Compare Purchase Prices
February 22, 2010
- 4 Therapies Approved as Advanced Therapies
February 22, 2010
- METI to Foster Pharma Industry as Driver of Economic Growth
February 22, 2010
- Mergers May Take Place between Generic Companies: Mr Sawai
February 22, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…